Back

Looking to connect with folks in clinical diagnostics and molecular biology! I’m building a new clinical lab focused on infectious disease diagnostics powered by DNA sequencing — and would love to connect with people who have experience in: • Runni

Can Sequencing replace traditional diagnostics in India? Traditional diagnostics are slow. Culture and antibiotic resistance tests take days or even weeks to deliver results. This can be detrimental for patients suffering from sepsis or fever of unk

💡 Did you know India🇮🇳 is leading a 𝐠𝐞𝐧𝐨𝐦𝐢𝐜 𝐫𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧? The 𝐆𝐞𝐧𝐨𝐦𝐞𝐈𝐧𝐝𝐢𝐚 𝐏𝐫𝐨𝐣𝐞𝐜𝐭 is leading the way for a genomic revolution. What this means? ✅ 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞: By developing a 𝐫

Why qPCR & Phenotypic Testing Must Be Displaced? – Part III This is the third part of a deep dive into why qPCR & phenotypic testing need to be replaced. In Part I, I covered the limitations of current diagnostics & why incremental improvements aren

After selling his bootstrapped startup Wingify for $200 million, Paras Chopra is diving into artificial intelligence. His next big project is a foundational AI research lab in India, focused on building advanced models and algorithms for the world.

Why qPCR & Phenotypic Testing Must Be Displaced – Part II If you ever want to understand the scale of a problem, look at how much it costs. Tuberculosis alone costs India, Africa, and Brazil 27 trillion INR a year in lost productivity and healthcare

🚀 Seeking Funding for Innovative Health Tech Startup I’m excited to share that I’m working on a groundbreaking health tech startup, currently at the idea stage. We aim to revolutionize patient care, diagnostics, telemedicine.. Our goal is improve

I am Ashwin Kumar Chena, a healthcare entrepreneur and innovator with over 17 years of experience in diagnostics, hospital operations, and healthcare marketing. My journey began in 2007 as a Medical Lab Technician, where I developed strong technical

📰 🚨 Big Pharma Meets Big AI: AstraZeneca Signs AI-Powered Research Deal in China! 🇨🇳🧠💊 In a move that could reshape chronic disease treatment, pharma giant AstraZeneca has teamed up with China’s CSPC Pharmaceutical Group to supercharge medical